spacer
home > ebr > winter 2019 > the impact of brexit on the pharma industry
PUBLICATIONS
European Biopharmaceutical Review

The Impact of Brexit on the Pharma Industry

Brexit: with negotiations still ongoing at the time of writing and the situation changing almost daily, it is not surprising that concerns are elevated in pharmaceutical circles – both within the UK and across mainland Europe. Looking at the potential impact of Brexit and the import and export of products between the UK and the EU every month, an important question is: how will this trade keep flowing without major disruption? Everyone is aware of uncertainty at the moment – not just for the UK, but also for the EU manufacturers supplying into it – but, as negotiations continue, industry should prepare itself for the possibility of change.

This is largely attributable to the UK government’s ‘red lines’: according to these, people will not have free movement and being able to freely negotiate global trade deals is required. Additionally, reducing contributions to the EU budget is desired, as well as being free from its courts of justice, and, finally, regulatory autonomy requirements.

If these red lines remain inflexible, but obstacles stalling the negotiation can be overcome, one scenario is that the UK could end up with a Canadian-style deal with the EU, where the country has almost completely tariff-free trade with the EU, but with greater regulatory barriers than member states.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Lynne Byers is the Executive Director of Pharmaceuticals and Biotechnology at NSF International. She graduated in chemistry in 1985. During her career, which spans more than 35 years, Lynne has gained extensive knowledge in the pharmaceutical manufacturing management and quality assurance (QA) areas, working as Global Head (Vice President) of external supply operations QA for Novartis and as Head of Inspectorate and Licensing for the MHRA, before joining NSF International in 2017. Her areas of expertise include QP training, packaging and labelling control GMP legislation, API manufacture and control, auditing and self-inspection skills, education of auditors, supply chain distribution, quality management of pharmaceutical suppliers, quality management of contract manufacturers, and affiliate quality assurance.
spacer
Lynne Byers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo starts to operate at Istanbul Airport its new hub

Turkish Cargo, the global air cargo brand, will perform its cargo transportation operations via passenger flights at the temporary satellite facility, which is completely satisfactory in terms of infrastructure at Istanbul Airport, as of April 6, 2019 at the same level of quality and care as previously.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

ASGCT 22nd Annual Meeting

29 April - 2 May 2019, Washington Hilton, Washington, D.C

The 2019 ASGCT Annual Meeting is expected to be the largest in Society history, eclipsing the mark set by the 2018 meeting just last year. Join more than 3,500 researchers, clinicians, advocates, and industry leaders in discovering the latest science and technology surrounding gene and cell therapy.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement